UNSPSC 51422215: Triamcinolone diacetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A73MM2Q32P, chemically known as 16alpha,21-diacetoxy-9alpha-fluoro-11beta,17alpha-dihydroxy-1,4-pregnadiene-3,20-dione but more generally known as triamcinolone diacetate, which bears US NIH Compound Identifier 6216. European Medicines Agency schedules Triamcinolone diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04938MIG.

UNSPSC 51422215 Triamcinolone diacetate is a Commodity code that nominally covers a specific corticosteroid pharmaceutical product, but recent state and local procurement activity under this code shows a mismatch: the two opportunities posted are for naloxone procurement and direct-to-manufacturer pharmacy benefit programs, neither of which fall within the scope of triamcinolone diacetate. The code shows little relevant recent activity aligned with its stated pharmaceutical scope. State and local health agencies and human services commissions are the primary issuing bodies when activity does occur under pharmaceutical codes in this family, but the current record does not support substantive procurement momentum in triamcinolone diacetate specifically.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a response deadline of July 26, 2023, while the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs. The geographic spread is limited — Florida and Texas — and the opportunities are peripheral to triamcinolone diacetate procurement. Without recent solicitations directly aligned to the code's nominal scope, the category presents minimal pursuit opportunity at this time.